Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03827031

Impact of Mulstidisciplinary Medication Assessment Review in Surgery Departments

The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chu de Grenoble, Grenoble, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient (or their representative) has given his consent and signed the consent form.
  • The patient is affiliated to a health insurance programme.
  • The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
  • The patient is available for a follow-up of 3 months.
  • The patient is hospitalized in the surgery department.
  • Patient with a Trivalle score greater than or equal to 2 (≥).
  • Patient living in a nursing home or going back home after hospitalization.

Exclusion criteria

  • The subject is participating in another category I interventional study.
  • The subject is in an exclusion period determined by another study.
  • The subject is under safeguard of justice.
  • It is not possible to give the patient (or his/her trusted-person) informed information.
  • Palliative care

Treatment and study plan

Mutlidisciplinary medication Review (MMR)

Other

The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted

Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up

Other

Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.

Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.

Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted.

Primary outcomes

  1. Change in iatrogenic drug risk in intervention groups versus control group

    Time frame: 3 months after hospitalization

    Proportion of patients transitioning from intermediate or high to low risk according to Trivalle score (a score between 0-10. A score 0-1 constitutes a low ADE risk (12%), score 2-5 represents an average risk (32%), and a score 6-10 represents a high risk (53%)

Secondary outcomes

  1. Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups

    Time frame: Hospital discharge (maximum 30 days)

    Number of modifications accepted/number of modifications proposed

  2. Number of potentially inappropriate medications per patient in each group

    Time frame: Hospital discharge (maximum 30 days)

  3. Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent

    Time frame: 3 months after hospital discharge

    Number of modifications accepted/number of modifications proposed

  4. Number of potentially inappropriate medications per patient in each group

    Time frame: 3 months after hospital discharge

  5. Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2)

    Time frame: Hospital discharge (maximum 30 days)

    Hours

  6. Time required for ransmitting multidisciplinary correspondence documents in B2 group

    Time frame: Hospital discharge (maximum 30 days)

    Hours

  7. Number of multidisciplinary correspondence documents sent to the community acotors in B2 group

    Time frame: Hospital discharge (maximum 30 days)

  8. Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group

    Time frame: Hospital discharge (maximum 30 days)

    email, fax or letter

  9. Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group

    Time frame: Hospital discharge (maximum 30 days)

  10. Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group

    Time frame: 2 months post discharge

  11. Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2

    Time frame: 2 months post hospital discharge

  12. Rate of patients with at least one rehospitalization in each group

    Time frame: 3 months after hospital discharge

  13. Mortality rate in each group

    Time frame: 3 months after hospital discharge

  14. Healthcare team satisfaction in interventional groups (B1, B2)

    Time frame: 3 months after hospital discharge

    Custom-built 7-part questionnaire

  15. patient satisfaction in all groups (A, B1, B2)

    Time frame: 3 months after hospital discharge

    questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Jean-Marie Kinowski

CONTACT

[email protected]

+33(0)4.66.68.31.04

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

Implementation and Impact of Multidisciplinary Medication Review in Surgery Departments on Medication Management of Elderly Patients

Acronym: CHIROPMEV

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Feb 1, 2019
Registry last updated
Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.